{"id":815520,"date":"2025-02-20T08:07:29","date_gmt":"2025-02-20T13:07:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/"},"modified":"2025-02-20T08:07:29","modified_gmt":"2025-02-20T13:07:29","slug":"vyne-therapeutics-to-participate-in-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/","title":{"rendered":"VYNE Therapeutics to Participate in March Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BRIDGEWATER, N.J., Feb.  20, 2025  (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in two investor conferences in March.<\/p>\n<p>Details are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:70%;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\">\n            <strong>TD Cowen 45<\/strong><br \/>\n            <sup><br \/>\n              <strong>th<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Health Care Conference, Boston, MA<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%\">Conference Date:<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:74%;width:74%;min-width:74%\">March 4, 2025<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>\u00a0<\/td>\n<td>Fireside chat and one-on-one meetings<\/td>\n<\/tr>\n<tr>\n<td>Fireside Chat Timing:<\/td>\n<td>\u00a0<\/td>\n<td>Tuesday, March 4, 2025, 11:10 AM ET<\/td>\n<\/tr>\n<tr>\n<td>Registration:\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\n            <a href=\"https:\/\/wsw.com\/webcast\/cowen177\/vyne\/2053782\" rel=\"nofollow\" target=\"_blank\">Webcast link<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\">\n            <strong>Leerink Partners Global Healthcare Conference, Miami, FL<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Conference Date:<\/td>\n<td>\u00a0<\/td>\n<td>March 11, 2025<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>\u00a0<\/td>\n<td>One-on-one meetings<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>A webcast replay will be available on the VYNE website for 90 days following the event.<\/p>\n<p>\n        <strong>About VYNE Therapeutics Inc. <\/strong><br \/>\n        <br \/>VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE\u2019s unique and proprietary BET inhibitors, which comprise its InhiBET\u2122 platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.\u00a0<\/p>\n<p>For more information about VYNE Therapeutics Inc. or its product candidates, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fRl_EuJJsoFUnHDoww0gxJd8XXsFemkC-CQ76BtPV5FoSUCZXzRlMKoN8XiAPv2Mc22jcf3vYZEh6sVeTBjcHozzUay4OIWXjj7NuvtxzLQ=\" rel=\"nofollow\" target=\"_blank\">www.vynetherapeutics.com<\/a>. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE\u2019s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), public conference calls, and webcasts.<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>John Fraunces<br \/>LifeSci Advisors, LLC<br \/>917-355-2395<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m5aSs1kmW0jrxdycMAvHxUNGdvStFkZ3upTH48pOryM0_nB5cryrZpxl1fGYib0EpJjR0EEtf2vDS7KAPqZWvCuzbARWUzMDE2TKBJ9f7QikbXE3hfHNmBq4lGr6qkzY\" rel=\"nofollow\" target=\"_blank\">jfraunces@lifesciadvisors.com<\/a><\/p>\n<p>Tyler Zeronda<br \/>VYNE Therapeutics Inc.<br \/>908-458-9106<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pV-v_h_5kotian6cu-BdgHXFjt4NPhYVWK5eV5qRSuYJ1QhgQEYVqj1FL5tfP759gBRPKBqDtejeQIaWhIzutESZ3iBU99NuGE_bWMKn-N0=\" rel=\"nofollow\" target=\"_blank\">Tyler.Zeronda@vynetx.com<\/a><\/p>\n<p>\n        <strong>Media Relations: <\/strong><br \/>\n        <br \/>Mike Beyer<br \/>Sam Brown Inc.<br \/>312-961-2502<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9yawhG3HZlgsDaXyWQBpaqSFbpt97Do0WTC-WNwpww2E8hsx_MZrTIo1-rKMZey0n3Wfhhynvm5rQRp4BfRAReB7_KJYZ1v3vOaeokOhGgI=\" rel=\"nofollow\" target=\"_blank\">mikebeyer@sambrown.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tv4ClGtKHic5O6OMxWWcVwyUlzkJhuaAVJDsUEZ4Qu4jeCO4YyGgLzYbbt9VVN1p7JMpHmbxd_JnFTjGWEv_NA==\" rel=\"nofollow\" target=\"_blank\"><br \/><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjcyZTI0ZTctYzhiZC00NWVmLTlkMTMtMzRlZGMwODZlNmNjLTExMDUzNzQ=\/tiny\/VYNE-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45 th Annual Health Care Conference, Boston, MA Conference Date: \u00a0 March 4, 2025 Format: \u00a0 Fireside chat and one-on-one meetings Fireside Chat Timing: \u00a0 Tuesday, March 4, 2025, 11:10 AM ET Registration:\u00a0 \u00a0 Webcast link \u00a0 \u00a0 \u00a0 Leerink Partners Global Healthcare Conference, Miami, FL Conference Date: \u00a0 March 11, 2025 Format: \u00a0 One-on-one meetings \u00a0 \u00a0 \u00a0 A webcast replay will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VYNE Therapeutics to Participate in March Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815520","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45 th Annual Health Care Conference, Boston, MA Conference Date: \u00a0 March 4, 2025 Format: \u00a0 Fireside chat and one-on-one meetings Fireside Chat Timing: \u00a0 Tuesday, March 4, 2025, 11:10 AM ET Registration:\u00a0 \u00a0 Webcast link \u00a0 \u00a0 \u00a0 Leerink Partners Global Healthcare Conference, Miami, FL Conference Date: \u00a0 March 11, 2025 Format: \u00a0 One-on-one meetings \u00a0 \u00a0 \u00a0 A webcast replay will be &hellip; Continue reading &quot;VYNE Therapeutics to Participate in March Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T13:07:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VYNE Therapeutics to Participate in March Investor Conferences\",\"datePublished\":\"2025-02-20T13:07:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/\",\"name\":\"VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\",\"datePublished\":\"2025-02-20T13:07:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-participate-in-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYNE Therapeutics to Participate in March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk","og_description":"BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE\u2019s management will participate in two investor conferences in March. Details are as follows: TD Cowen 45 th Annual Health Care Conference, Boston, MA Conference Date: \u00a0 March 4, 2025 Format: \u00a0 Fireside chat and one-on-one meetings Fireside Chat Timing: \u00a0 Tuesday, March 4, 2025, 11:10 AM ET Registration:\u00a0 \u00a0 Webcast link \u00a0 \u00a0 \u00a0 Leerink Partners Global Healthcare Conference, Miami, FL Conference Date: \u00a0 March 11, 2025 Format: \u00a0 One-on-one meetings \u00a0 \u00a0 \u00a0 A webcast replay will be &hellip; Continue reading \"VYNE Therapeutics to Participate in March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T13:07:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VYNE Therapeutics to Participate in March Investor Conferences","datePublished":"2025-02-20T13:07:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/","name":"VYNE Therapeutics to Participate in March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=","datePublished":"2025-02-20T13:07:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTUxNyM2NzU5OTIyIzIwOTM4MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-participate-in-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VYNE Therapeutics to Participate in March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815520"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815520\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}